Tvardi Operating Cycle from 2010 to 2025
| TVRD Stock | 4.00 0.02 0.50% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 634.43965431 | Current Value 666.16 | Quarterly Volatility 254.20884919 |
Check Tvardi Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tvardi Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 182.4 K, Total Revenue of 6.8 M or Other Operating Expenses of 92.3 M, as well as many indicators such as Price To Sales Ratio of 0.74, Dividend Yield of 0.0 or Days Sales Outstanding of 241. Tvardi financial statements analysis is a perfect complement when working with Tvardi Therapeutics, Valuation or Volatility modules.
Tvardi | Operating Cycle | Build AI portfolio with Tvardi Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tvardi Therapeutics, is a strong investment it is important to analyze Tvardi Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tvardi Therapeutics,'s future performance. For an informed investment choice regarding Tvardi Stock, refer to the following important reports:Check out the analysis of Tvardi Therapeutics, Correlation against competitors. For information on how to trade Tvardi Stock refer to our How to Trade Tvardi Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tvardi Therapeutics,. If investors know Tvardi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tvardi Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) |
The market value of Tvardi Therapeutics, is measured differently than its book value, which is the value of Tvardi that is recorded on the company's balance sheet. Investors also form their own opinion of Tvardi Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Tvardi Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tvardi Therapeutics,'s market value can be influenced by many factors that don't directly affect Tvardi Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tvardi Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Tvardi Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tvardi Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.